[Inhalation combination therapy in chronic obstructive lung disease. TRISTAN-study].
Seeger
W
W
Medizinische Klink II, Universitätsklinikum Giessen. werner.seeger@innere.med.uni-giessen.de
Schulz
R
R
D000280:Administration, Inhalation; D000318:Adrenergic beta-Agonists / Q000008:administration & dosage; D000336:Aerosols / Q000008:administration & dosage; D000420:Albuterol / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D000730:Androstadienes / Q000008:administration & dosage*; D001993:Bronchodilator Agents / Q000008:administration & dosage; D004311:Double-Blind Method; D004338:Drug Combinations; D000068298:Fluticasone; D006801:Humans; D038622:Internationality; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy* / Q000453:epidemiology*; D000068299:Salmeterol Xinafoate; D016896:Treatment Outcome
D000318:Adrenergic beta-Agonists; D000336:Aerosols; D000730:Androstadienes; D001993:Bronchodilator Agents; D004338:Drug Combinations; D000068299:Salmeterol Xinafoate; D000068298:Fluticasone; D000420:Albuterol